Nordson
NDSN
327.69
-6.53
-1.95%
Nordson
US · NDSN
#983 by market cap
Listed 1970
327.69
-6.53
-1.95%
Live - 5344 symbols - heartbeat 400s ago
· 2026-10-08 07:01
Pre-market
327.69
0.00%
After-hours
327.69
0.00%
Overnight
323.37
-1.32%
- Market cap
- 18.25B
- P/E (TTM)i
- 33.17
- P/Bi
- 5.58
- EPSi
- 8.51
- Div yieldi
- 1.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on NDSN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 82.57% -0.04pp
- Institutions
- 879 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund64.86%
Private Company7.29%
Individual/Insider5.64%
Public Company3.49%
Hedge Fund2.66%
Government Pension Fund2.23%
Sovereign Wealth Fund1.38%
Family Office/Trust0.31%
Insurance Company0.16%
Other11.98%
Top holders as of 2026-06-30
BlackRock
7.43% · 4.14M sh
Vanguard Capital Management, LLC
6.76% · 3.76M sh
State Street Global Advisors
5.34% · 2.98M sh
Jennifer Savage
5.29% · 2.95M sh
Vanguard Portfolio Management, LLC
4.24% · 2.36M sh
Nord family descendants
3.75% · 2.09M sh
Geode Capital Management, LLC
3.42% · 1.91M sh
Kayne Anderson Rudnick Investment Management, LLC
3.08% · 1.71M sh
Eaton Vance Management
2.06% · 1.14M sh
Invesco Capital Management LLC
1.98% · 1.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Sundaram Nagarajan | Chief Executive Officer | 0.13% |
| James DeVries | Executive Vice President of Continuous Improvement | 0.09% |
| Victor Richey | Independent Director | 0.04% |
| Frank Jaehnert | Independent Director | 0.03% |
| Ginger Jones | Independent Director | 0.01% |
| John DeFord | Independent Director | 0.01% |
| Srinivas Subramanian | -- | 0.01% |
| Jennifer A. Parmentier | Independent Director | 0.01% |
| Jennifer McDonough | General Counsel | 0.01% |
| Stephen Lovass | Executive Vice President of Medical and Fluid Solutions | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Joseph Rutledge | Chief Accounting Officer | Open Market Disposition | -684 | $309.38 |
| 2026-09-01 | Milton Morris | Independent Director | Open Market Disposition | -156 | $316.63 |
| 2026-08-31 | Justin Hall | Executive Vice President of Medical & Fluid Solutions | Sale to Issuer | -118 | $314.40 |
| 2026-08-26 | Jennifer McDonough | General Counsel | Open Market Disposition | -260 | $336.00 |
| 2026-08-25 | Daniel Hopgood | Chief Financial Officer | Derivative Exercise and Sale | -1,329 | $209.73–334.29 |
| 2026-07-30 | John DeFord | Independent Director | Other Acquisition | +84 | $297.78 |
| 2026-07-30 | Christopher Mapes | Director | Other Acquisition | +42 | $297.78 |
| 2026-07-30 | Joseph Rutledge | Chief Accounting Officer | Sale to Issuer | -274 | $297.78 |
| 2026-06-03 | James DeVries | Executive Vice President of Continuous Improvement | Intent to Sell (Form 144) | -6,600 | $290.00 |
| 2026-05-31 | Daniel Hopgood | Chief Financial Officer | Sale to Issuer | -148 | $281.31 |
| 2026-04-30 | Annette Clayton | Chairwoman | Other Acquisition | +270 | $283.20 |
| 2026-04-29 | John DeFord | Independent Director | Other Acquisition | +87 | $288.45 |
| 2026-04-29 | Christopher Mapes | Director | Other Acquisition | +43 | $288.45 |
| 2026-04-16 | Srinivas Subramanian | -- | Automatic Disposition | -1,200 | $280.00 |
| 2026-04-16 | Srinivas Subramanian | -- | Derivative Exercise and Sale | -1,900 | $107.65–280.00 |
| 2026-04-15 | James DeVries | Executive Vice President of Continuous Improvement | Sale to Issuer | -198 | $275.28 |
| 2026-04-14 | Milton Morris | Independent Director | Open Market Disposition | -245 | $273.87 |
| 2026-04-07 | Justin Hall | Executive Vice President of Medical & Fluid Solutions | Open Market Disposition | -716 | $275.82 |
| 2026-02-26 | Sarah Siddiqui | Executive Vice President | Sale to Issuer | -30 | $293.44 |
| 2026-02-23 | Joseph Kelley | Chief Financial Officer | Intent to Sell (Form 144) | -8,725 | $293.04 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:01:27 · For reference only, not investment advice and not tailored to your situation.